Site icon Duncan Bucknell

Pharma & Biotech Global Week in Review 14 March 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.


Highlights this week included:

Nexavar (Sorafenib) – India’s first compulsory license granted!: Bayer v Natco (Spicy IP) (Apothecurry) (IP Watch) (KEI) (IAM)


Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.



Neglected tropical disease (infectious diseases) drugs: What are they telling us about innovations! (profitability through simplicity)

Genetic heterogeneity in tumor samples may explain difficulties in developing personalized medicine (Patent Docs)

Europe moving away from pay-for-delay? (IP Whiteboard)

Kenya waits on landmark decision affecting access to drugs due out today (Afro-IP)

Mexico defines orphan drugs, but leaves questions unanswered (IP tango)

US: FDA cements “it’s our party and we’ll punt if we want to” stance on 180-day exclusivity failure to obtain tentative approval forfeiture decisions (FDA Law Blog)

US: Lawsuits allege that coupons and savings programs for brand-name drugs violate RICO, antitrust law (FDA Law Blog)

US: Safe harbor does not apply to products not requiring regulatory approval: PSN Illinois v Abbott Labs (Chicago IP Litigation Blog)

US: Attacks on Medtronic & OrbusNeich medical device patents among the reexamination requests filed the week of March 5, 2012 (WHDA)



Crestor (Rosuvastatin) – Australia: Generics unsuccessful in Crestor injunction challenges: Apotex v AstraZeneca and Watson Pharma v AstraZeneca (Patentology) (Patentology)

Gleevec (Imatinib) – India: Supreme Court to rule on Gleevac patent: Novartis v Union of India (Patent Docs) (Spicy IP)

Megace ES (Megestrol Acetate) – US: FDA’s brief in Par: the gift that keeps on giving (FDA Law Blog)

Nexavar (Sorafenib) – India’s first compulsory license granted!: Bayer v Natco (Spicy IP) (Apothecurry) (IP Watch) (KEI) (IAM)

Oxycodone – EU: An unfinished battle and an undisclosed question – infringement proceedings in UK, Netherlands, Germany, Norway and Finland and EPO opposition re EP 722 730 (Kluwer Patent Blog)

Seroquel (Quetiapine) – Netherlands: District Court of The Hague denies requested invalidation of sustained release quetiapine patent: Sandoz v AstraZeneca (EPLAW)

Exit mobile version